Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma.
Schaff LR, Piotrowski AF, Pentsova E, Gavrilovic IT, Lin A, Kaley TJ, Wongchai V, Emadi-Paramkouhi L, Madzsar J, Quinn L, Gonzalez A, Breakey L, Tang SS, Mendez JS, Malani R, Nolan C, Hatzoglou V, Young RJ, DeAngelis LM, Reiner AS, Panageas KS, Francis JH, Mellinghoff IK, Grommes C.
Schaff LR, et al. Among authors: tang ss.
Neuro Oncol. 2025 Sep 17;27(8):2107-2116. doi: 10.1093/neuonc/noaf104.
Neuro Oncol. 2025.
PMID: 40269592
Clinical Trial.